BioSpecifics Technologies Corp (BSTC)
(Delayed Data from NSDQ)
$66.72 USD
+0.21 (0.32%)
Updated May 3, 2019 04:00 PM ET
After-Market: $66.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.72 USD
+0.21 (0.32%)
Updated May 3, 2019 04:00 PM ET
After-Market: $66.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss
by Zacks Equity Research
Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.
What's in Store for BioSpecifics (BSTC) This Earnings Season?
by Zacks Equity Research
BioSpecifics Technologies (BSTC) will provide updates on Xiaflex and pipeline progress, when it releases first-quarter 2019 results.
Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%
by Zacks Equity Research
Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.
Weekly Jobless Claims Lowest in Nearly 50 Years: 5 Top Picks
by Nalak Das
The U.S. labor market is the major driver of the bull run, which is more than a decade old.
Zogenix Gets Refusal to File Letter From FDA for Seizure Drug
by Zacks Equity Research
Zogenix (ZGNX) receives a Refusal to File letter from the FDA regarding its NDA for Fintepla for the treatment of seizures associated with Dravet syndrome.
United Therapeutics Discontinues PAH Drug After Study Fails
by Zacks Equity Research
United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.
3 Reasons Why BioSpecifics (BSTC) Is a Great Growth Stock
by Zacks Equity Research
BioSpecifics (BSTC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
5 Stocks With Recent Price Strength Despite Market Volatility
by Nalak Das
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Zacks.com featured expert Kevin Matras highlights: Darden Restaurants, Best Buy, BioSpecifics Technologies and ONEOK
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Darden Restaurants, Best Buy, BioSpecifics Technologies and ONEOK
4 Top Stocks to Buy for Superb Earnings Growth
by Tirthankar Chakraborty
We highlight stocks that have striking earnings growth and positive estimate revisions.
BioSpecifics (BSTC) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
BioSpecifics (BSTC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What's in Store for BioSpecifics (BSTC) This Earnings Season?
by Zacks Equity Research
BioSpecifics (BSTC) is expected to provide updates on Xiaflex and its pipeline candidates in its fourth quarter earnings call.
BioSpecifics (BSTC) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
BioSpecifics (BSTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is BioSpecifics Technologies (BSTC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (BSTC) Outperforming Other Medical Stocks This Year?
Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza
by Zacks Equity Research
Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.
INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data
by Zacks Equity Research
INSYS Therapeutics' (INSY) epinephrine nasal spray demonstrates pharmacokinetic profile similar to two reference products EpiPen and Adrenalin in treating patients with anaphylaxis, a life-threatening allergic reaction.
Weakness Seen in Champions Oncology (CSBR) Estimates: Should You Stay Away?
by Zacks Equity Research
Champions Oncology (CSBR) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Karyopharm Files MAA for Myeloma Candidate Selinexor in EU
by Zacks Equity Research
Karyopharm (KPTI) tenders a marketing application to European regulatory authority with the purpose of seeking an approval for selinexor to address patients with penta-refractory multiple myeloma.
Neurocrine Gives Ingrezza Sales View, Updates on Pipeline
by Zacks Equity Research
Neurocrine (NBIX) issues preliminary sales outlook for Ingrezza with respect to the fourth quarter of 2018 as well as the full year. The company also lends an update on its pipeline.
Verrica (VRCA) Catches Eye: Stock Jumps 6.9%
by Zacks Equity Research
Verrica (VRCA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Spectrum Pharma Fully Enrolls 1St Cohort in Poziotinib Study
by Zacks Equity Research
Spectrum Pharma (SPPI) completes enrollment in the first cohort of a phase II study on poziotinib for previously treated NSCLC patients with EGFR exon 20 insertion mutations. Shares rise.
Flexion Starts Phase III Enrollment on Zilretta for Hip OA
by Zacks Equity Research
Flexion (FLXN) initiates enrollment in phase III study on its pain drug, Zilretta, for the treatment of patients suffering hip osteoarthritis.
Portola Up as Large-Scale Andexxa Production Gets FDA Nod
by Zacks Equity Research
Portola Pharmaceuticals (PTLA) announces FDA approval for large-scale Generation II manufacturing process for Andexxa to support commercial launch expected this month.
Spectrum Pharma Files BLA for Neutropenia Candidate Rolontis
by Zacks Equity Research
Spectrum Pharma (SPPI) petitions for a BLA to the FDA regarding its lead pipeline candidate, Rolontis, to address chemotherapy-induced neutropenia in patients with breast cancer.
Is BioSpecifics Technologies (BSTC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BSTC) Outperforming Other Medical Stocks This Year?